UCHL1 and cancer: While to the best of our knowledge, we are the first to report efficacy of small molecule UCHL1 inhibition specifically in chemoresistant HGSOC cells, there have been a number of studies in cancer that have described UCHL1’s complex role in both chemo- and drug-resistance (Ding et al., 2020; Lu et al., 2021; Yang et al., 2018; Lee et al., 2021; Cucci et al., 2020; Ning et al., 2017; Jin et al., 2015; Brinkmann et al., 2013).